In Brief: Centocor's ReoPro
Executive Summary
Centocor's ReoPro: Phase III study in patients scheduled for angioplasty due to refractory unstable angina will be continued after interim data analysis and recommendation by independent safety and efficacy review committee, Centocor and partner Lilly announce. The CAPTURE (Chimeric 7e3 Antiplatelet in Unstable Angina Refractory to Standard Therapy) trial is being conducted in Europe. The antiplatelet MAb abciximab was approved in the U.S. Dec. 22 for treatment of patients undergoing PTCA who are at high risk for abrupt artery closure...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth